• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Specialties
  • Diabetes & Endocrinology
  • Page 7
Top 10 Weight Loss Pitfalls and How to Avoid Them: A Science-Based Guide
Posted inDiabetes & Endocrinology Family Medicine & Nutrition news Specialties

Top 10 Weight Loss Pitfalls and How to Avoid Them: A Science-Based Guide

Posted by By MedXY 08/17/2025
Uncover the ten most common weight loss misconceptions and pitfalls, and learn scientifically grounded practices to achieve sustainable, healthy fat loss.
Read More
Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena

Posted by By MedXY 08/17/2025
Eli Lilly's oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promising diverse mechanisms and potential market shifts.
Read More
Debunking Weight Loss Myths: Avoid These Pitfalls for More Effective and Healthy Weight Loss
Posted inDiabetes & Endocrinology news Specialties

Debunking Weight Loss Myths: Avoid These Pitfalls for More Effective and Healthy Weight Loss

Posted by By MedXY 08/17/2025
This article explores common weight loss misconceptions, offering scientific insights and strategies for safe and sustainable fat loss.
Read More
Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss
Posted inDiabetes & Endocrinology news Specialties

Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss

Posted by By MedXY 08/17/2025
Explore seven prevalent misconceptions about weight loss—from ignoring obesity as a disease to the dangers of rapid slimming—founded on medical evidence and expert advice to guide safe and effective weight management.
Read More
Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial
Posted inCardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

Posted by By MedXY 08/17/2025
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
Read More
Obicetrapib Shows Promise in Slowing Alzheimer’s Disease Progression Through Lipid Modulation
Posted inClinical Updates Diabetes & Endocrinology Neurology news Specialties

Obicetrapib Shows Promise in Slowing Alzheimer’s Disease Progression Through Lipid Modulation

Posted by By MedXY 08/17/2025
Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.
Read More
Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients
Posted inClinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

Posted by By MedXY 08/17/2025
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
Read More
Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes
Posted inDiabetes & Endocrinology news Specialties

Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes

Posted by By MedXY 08/17/2025
Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabetic patients.
Read More
Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial
Posted inCardiology Diabetes & Endocrinology news Specialties

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

Posted by By MedXY 08/17/2025
The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.
Read More
Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial
Posted inCardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

Posted by By MedXY 08/16/2025
The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.
Read More
SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes
Posted inClinical Updates Diabetes & Endocrinology news Specialties Urology

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes

Posted by By MedXY 08/14/2025
Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.
Read More
The Long-Term Legacy of Atorvastatin: Insights from the 20-Year ASCOT-Legacy Follow-Up
Posted inCardiology Diabetes & Endocrinology news Specialties

The Long-Term Legacy of Atorvastatin: Insights from the 20-Year ASCOT-Legacy Follow-Up

Posted by By MedXY 08/13/2025
The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.
Read More
Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial

Posted by By MedXY 08/13/2025
Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.
Read More
Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial
Posted inDiabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

Posted by By MedXY 08/13/2025
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.
Read More
Improving Patient Safety: The Role of Deprescribing Diabetes Medication in Older Adults
Posted inDiabetes & Endocrinology news Specialties

Improving Patient Safety: The Role of Deprescribing Diabetes Medication in Older Adults

Posted by By MedXY 08/11/2025
This study examines the effectiveness of physician academic detailing combined with previsit patient activation to increase diabetes medication deprescribing amongst older adults, aiming to reduce hypoglycemia-related complications.
Read More
Exploring Auricular Acupressure: A Promising Complementary Intervention for Older Adults with Type 2 Diabetes
Posted inDiabetes & Endocrinology Family Medicine & Nutrition news Specialties

Exploring Auricular Acupressure: A Promising Complementary Intervention for Older Adults with Type 2 Diabetes

Posted by By MedXY 08/11/2025
A recent study investigates auricular acupressure's effects on glycemic markers, stress, and sleep quality in older adults with Type 2 diabetes, revealing promising outcomes and potential for nursing interventions.
Read More
Diabetic Peripheral Neuropathy as a Predictor of Lacunar Stroke in Diabetes Patients
Posted inDiabetes & Endocrinology Neurology news Specialties

Diabetic Peripheral Neuropathy as a Predictor of Lacunar Stroke in Diabetes Patients

Posted by By MedXY 08/11/2025
A study reveals diabetic peripheral neuropathy (DPN) significantly associates with cerebral small-vessel disease (SVD), indicating a predictive role for lacunar stroke in diabetic patients and highlighting opportunities for early intervention.
Read More
Optimal Exercise Order for Glycemic Control in Postmenopausal Women with Type 2 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Optimal Exercise Order for Glycemic Control in Postmenopausal Women with Type 2 Diabetes

Posted by By MedXY 08/11/2025
This article reviews a study examining the effects of aerobic versus resistance exercise execution order on glycemia, blood pressure, and heart rate variability in postmenopausal women with type 2 diabetes, emphasizing clinical implications.
Read More
Optimizing Exercise for Health: The Impact of Aerobic and Resistance Training Order in Postmenopausal Women with Type 2 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Optimizing Exercise for Health: The Impact of Aerobic and Resistance Training Order in Postmenopausal Women with Type 2 Diabetes

Posted by By MedXY 08/11/2025
This study explores the effects of different exercise orders on glycemia, blood pressure, and heart rate variability in postmenopausal women with type 2 diabetes, highlighting some insights for clinical practice.
Read More
Predicting Long-Term Mortality: Insights from a Multi-Metabolite Signature in the PREDIMED Trial
Posted inDiabetes & Endocrinology news Specialties

Predicting Long-Term Mortality: Insights from a Multi-Metabolite Signature in the PREDIMED Trial

Posted by By MedXY 08/11/2025
A study identified a robust plasma multi-metabolite signature that predicts long-term all-cause mortality in participants from the PREDIMED trial and several US cohorts, providing new insights into metabolic biomarkers.
Read More

Posts pagination

Previous page 1 … 5 6 7 8 9 … 11 Next page
  • Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper
  • Real-World Effectiveness of Rituximab and Cyclophosphamide in Severe ANCA-Associated Vasculitis: Insights from J-CANVAS
  • Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study
  • Transportation Noise and Heart Disease: Updated Evidence and Implications from a 2025 Meta-Analysis
  • Impact of Outdoor Air Pollution and Traffic Noise on Allostatic Load in Children: Insights from Six European Cohorts
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation longevity mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial semaglutide sexual health treatment type 2 diabetes weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in